SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

被引:327
作者
Ye, Yumei [1 ]
Bajaj, Mandeep [2 ]
Yang, Hsiu-Chiung [3 ]
Perez-Polo, Jose R. [1 ]
Birnbaum, Yochai [4 ]
机构
[1] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA
[2] Baylor Coll Med, Dept Med, Endocrinol Sect, Houston, TX 77030 USA
[3] Astrazeneca, CVMD, iMED, Translat Sci, Molndal, Sweden
[4] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA
关键词
Diabetes mellitus; DPP-4; inhibitor; Fibrosis; Inflammation; SGLT-2; COTRANSPORTER; 2; INHIBITORS; REG OUTCOME TRIAL; CARDIOVASCULAR OUTCOMES; SELECTIVE INHIBITOR; HEPATIC STEATOSIS; OXIDATIVE STRESS; RISK; EMPAGLIFLOZIN; PHARMACOKINETICS; HYPERGLYCEMIA;
D O I
10.1007/s10557-017-6725-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice. (2) The effects can be augmented with saxagliptin (Saxa), a DDP4-inhibitor. (3) Dapa effect is possibly SGLT2-independent on cardiofibroblasts in vitro. Type 2 diabetic (BTBR ob/ob) and wild-type (WT) mice received vehicle, Dapa, or Dapa+Saxa for 8 weeks. Glucose tolerance test and echocardiogram were performed. Cardiofibroblasts from WT and BTBR hearts were incubated with Dapa and exposed to LPS. Left ventricular ejection fraction (LVEF) was 81 +/- 1% in the WT and 53 +/- 1% in the T2D-cont mice. Dapa and Dapa+Saxa improved LVEF to 68 +/- 1 and 74.6 +/- 1% in the BTBR mice (p < 0.001). The mRNA levels of NALP3, ASC, IL-1 beta, IL-6, caspase-1, and TNF alpha were significantly higher in the BTBR compared to the WT hearts; and Dapa and Dapa+Saxa significantly attenuated these levels. Likewise, protein levels of NLRP3, TNF alpha, and caspase-1 were higher in the BTBR compared to the WT hearts and Dapa, and to a greater extent Dapa+Saxa, attenuated the increase in the BTBR mice. Collagen-1 and collagen-3 mRNA levels significantly increased in the BTBR mice and these increases were attenuated by Dapa and Dapa+Saxa. P-AMPK/total-AMPK ratio was significantly lower in the BTBR mice than in the WT mice. Dapa and Dapa+Saxa equally increased the ratio in the BTBR mice. This in vitro study showed that NALP3, ASC, IL-1 beta, and caspase-1 mRNA levels were higher in the BTBR cardiofibroblasts and attenuated with Dapa. The effect was AMPK-dependent and SGLT1-independent. Dapa attenuated the activation of the inflammasome, fibrosis, and deterioration of LVEF in BTBR mice. The anti-inflammatory, anti-fibrotic effects are likely SGLT2- and glucose-lowering-independent, as they were replicated in the in vitro model. The effects on remodeling were augmented when Saxa was added to Dapa. Yet, adding Saxa to Dapa did not result in a greater effect on myocardial fibrosis and collagen levels.
引用
收藏
页码:119 / 132
页数:14
相关论文
共 49 条
  • [1] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
    Abdul-Ghani, Muhammad
    Del Prato, Stefano
    Chilton, Robert
    DeFronzo, Ralph A.
    [J]. DIABETES CARE, 2016, 39 (05) : 717 - 725
  • [2] NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner
    Anders, Hans-Joachim
    Lech, Maciej
    [J]. KIDNEY INTERNATIONAL, 2013, 84 (02) : 225 - 228
  • [3] The Inflammasomes in Kidney Disease
    Anders, Hans-Joachim
    Muruve, Daniel A.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (06): : 1007 - 1018
  • [4] Bae HR, 2016, BETAHYDROXYBUTYRATE
  • [5] Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
    Beckman, JA
    Creager, MA
    Libby, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19): : 2570 - 2581
  • [6] Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
    Benetti, Elisa
    Mastrocola, Raffaella
    Vitarelli, Giovanna
    Cutrin, Juan Carlos
    Nigro, Debora
    Chiazza, Fausto
    Mayoux, Eric
    Collino, Massimo
    Fantozzi, Roberto
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (01) : 45 - 53
  • [7] Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome
    Birnbaum, Yochai
    Bajaj, Mandeep
    Qian, Jinqiao
    Ye, Yumei
    [J]. BMJ OPEN DIABETES RESEARCH & CARE, 2016, 4 (01)
  • [8] Chang YK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158810
  • [9] DPP-4 Inhibitors Repress NLRP3 Inflammasome and Interleukin-1beta via GLP-1 Receptor in Macrophages Through Protein Kinase C Pathway
    Dai, Yao
    Dai, Dongsheng
    Wang, Xianwei
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (05) : 425 - 432
  • [10] Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
    Daniele, Giuseppe
    Xiong, Juan
    Solis-Herrera, Carolina
    Merovci, Aurora
    Eldor, Roy
    Tripathy, Devjit
    DeFronzo, Ralph A.
    Norton, Luke
    Abdul-Ghani, Muhammad
    [J]. DIABETES CARE, 2016, 39 (11) : 2036 - 2041